ABSTRACT

MCHIR ANTAGONISTS

The present invention provides compounds of formula (I), wherein R¹ represents a C₁₋₄ alkoxy group optionally substituted by one or more fluoro or a C₁₋₄alkyl group optionally substituted by one or more fluoro; n represents 0 or 1; R² represents a C₁₋₄alkyl group optionally substituted by one or more fluoro or a C₁₋₄alkoxy group optionally substituted by one or more fluoro; m represents 0 or 1; R³ represents H or a C₁₋₄alkyl group; L¹ represents an alkylene chain (CH₂), in which r represents 2 or 3 or L¹ represents a cyclohexyl group wherein the two nitrogens bearing R³ and R⁴, respectively, are linked to the cyclohexyl group either via the 1.3 or the 1.4 positions of the cyclohexyl group or L¹ represents a cyclopentyl group wherein the two nitrogens bearing R³ and R⁴, respectively, are linked to the cyclopentyl group via the 1,3 position of the cyclopentyl group and additionally when R⁵ represents 9, 10-methanoanthracen-9(10H)-yl the group -L¹-N(R⁴)- together represents a piperidyl ring which is linked to L² through the piperidinyl nitrogen and to N-R³ via the 4 position of the piperidyl ring with the proviso that when R⁵ represents 9, 10methanoanthracen-9(10H)-vl then r is only 2; R⁴ represents H or a C₁₋₄alkyl group optionally substituted by one or more of the following: an aryl group or a heteroaryl group: L² represents a bond or an alkylene chain (CH₂)_s in which s represents 1, 2 or 3 wherein the alkylene chain is optionally substituted by one or more of the following: a C₁₋₄alkyl group, phenyl or heteroaryl; R⁵ represents aryl, a heterocyclic group or a C₃₋₈cycloalkyl group which is optionally fused to a phenyl or to a heteroaryl group; as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, thereof; with provisos, processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions containing them.